Bristol-Myers Squibb Reports Q2 2026 Earnings and Strategic Updates
In its second-quarter earnings call, Bristol-Myers Squibb (NYSE: BMY) highlighted strong performance from its growth portfolio, which now accounts for nearly 60% of total revenue. Eliquis saw demand-driven growth of 21%, while Opdivo's decline was attributed to a strategic shift toward Qvantig in the U.S., which is annualizing at over $1 billion. The company announced new AI partnerships with Anthropic and NVIDIA, aiming to enhance disease biology understanding and drug development efficiency. Strategic cost-saving initiatives are enabling reinvestment into high-value growth areas. Management also raised full-year revenue and adjusted EPS guidance due to strong first-half performance and higher-than-expected Eliquis sales. Looking ahead, key pipeline milestones include potential readouts for admilparant in pulmonary fibrosis and Sotyktu in lupus by year-end 2026. A $1.5 billion to $2 billion revenue decline is expected in 2027 due to Eliquis patent expiry in Europe.